Mentions of robotics within the filings of companies in the pharmaceutical industry rose 25% between the first and second quarters of 2021.
In total, the frequency of sentences related to robotics between July 2020 and June 2021 was 100% higher than in 2016 when GlobalData, from whom our data for this article is taken, first began to track the key issues referred to in company filings.
When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Robotics is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.
Machine learning hiring levels in clinical trials rose to a year-high in April 2022By
To assess whether robotics is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned robotics at least once in filings during the past twelve months - this was 9% compared to 2% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to robotics.
Of the 40 biggest employers in the pharmaceutical industry, Johnson & Johnson was the company which referred to robotics the most between July 2020 and June 2021. GlobalData identified seven robotics-related sentences in the United States-based company's filings - 0.06% of all sentences. ICON Plc mentioned robotics the second most - the issue was also referred to in 0.06% of sentences in the company's filings. Other top employers with high robotics mentions included Bayer AG, Grifols SA and Takeda Pharmaceutical Co Ltd.
This analysis provides an approximate indication of which companies are focusing on robotics and how important the issue is considered within the pharmaceutical industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning robotics more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company's ventures into robotics have been successes or failures.
In the last quarter, pharmaceutical companies based in Asia were most likely to mention robotics with 0.01% of sentences in company filings referring to the issue. In contrast, companies with their headquarters in Western Europe mentioned robotics in just 0.01% of sentences.